

Saskatchewan Biosimilars Initiative

Concluded Transition Periods

Drug Plan and Extended Benefits Branch
3475 Albert Street
REGINA SK S4S 6X6
Phone: 1-800-667-2549 (306-787-8744 in Regina)
(option 2, then 2)
Email: sk.biosimilars@health.gov.sk.ca

Drug Name	Reference Biologic Brand Name (switch from)	Biosimilar Brand Name (switch to)*	Health Conditions
End of Transition Period: July 31, 2026			
Omalizumab	Xolair®	Omlyclo®	Chronic idiopathic urticaria**
Tocilizumab	Actemra®	Avtozma™ Tyenne®	Autoimmune conditions (giant cell arteritis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis)
Ustekinumab	Stelara®	Jamteki™ Otulfi™ Steqeyma® Wezlana™	Autoimmune conditions (plaque psoriasis, psoriatic arthritis, Crohn's disease)

*Please refer to the Saskatchewan Formulary for the most current listings.

**Omlyclo is also listed on the Saskatchewan Formulary as an Exception Drug Status (EDS) benefit for other conditions.